[
  {
    "ts": null,
    "headline": "Snap downgraded, Leidos upgraded: Wall Street's top analyst calls",
    "summary": "Snap downgraded, Leidos upgraded: Wall Street's top analyst calls",
    "url": "https://finnhub.io/api/news?id=fcfbd0349c8249b4a80557cd84fc990ceea21995be91665365d94e5bf78eb230",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754487400,
      "headline": "Snap downgraded, Leidos upgraded: Wall Street's top analyst calls",
      "id": 136237354,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "Snap downgraded, Leidos upgraded: Wall Street's top analyst calls",
      "url": "https://finnhub.io/api/news?id=fcfbd0349c8249b4a80557cd84fc990ceea21995be91665365d94e5bf78eb230"
    }
  },
  {
    "ts": null,
    "headline": "Actuate Therapeutics To Collaborate with Incyte Corporation and the University of Pittsburgh on Clinical Trial of Elraglusib in Combination with Retifanlimab and mFOLFIRINOX in Patients with Advanced Pancreatic Cancer",
    "summary": "Clinical Trial Study to be Conducted at UPMC Hillman Cancer to Evaluate Novel Combination as Frontline Therapy CHICAGO and FORT WORTH, Texas, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced the initiation of the Phase 1b t",
    "url": "https://finnhub.io/api/news?id=5799158a359354017e60277051d256ee630c8aee3dd33c8b8f7ce876c68af395",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754484300,
      "headline": "Actuate Therapeutics To Collaborate with Incyte Corporation and the University of Pittsburgh on Clinical Trial of Elraglusib in Combination with Retifanlimab and mFOLFIRINOX in Patients with Advanced Pancreatic Cancer",
      "id": 136237563,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "Clinical Trial Study to be Conducted at UPMC Hillman Cancer to Evaluate Novel Combination as Frontline Therapy CHICAGO and FORT WORTH, Texas, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced the initiation of the Phase 1b t",
      "url": "https://finnhub.io/api/news?id=5799158a359354017e60277051d256ee630c8aee3dd33c8b8f7ce876c68af395"
    }
  }
]